Wikipedia Disease Information Worth Monitoring By Pharma Companies, IMS Says
Executive Summary
An analysis of Wikipedia page visits over the last two years shows that rarer diseases had a higher frequency of visits than many more common conditions, IMS Institute for Health Informatics says.
You may also be interested in...
FDA’s Social Media Guidance Gives Firms A Pass On User-Generated Content
The draft guidance outlines substantial reporting requirements for websites that firms control and for content on third-party sites – as well as saying when FDA intends to use enforcement discretion.
Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.